<DOC>
	<DOCNO>NCT01939158</DOCNO>
	<brief_summary>The purpose study compare immediate long term ( 5 year ) immunogenicity safety GSK Biologicals ' MenACWY-TT vaccine give single dose 2 dose toddler age 12 14 month . Also , study also assess co-administration GSK Biologicals ' MenACWY-TT booster dose Pfizer 's Prevenar 13 adversely impact immunogenicity either vaccine .</brief_summary>
	<brief_title>Immunogenicity Safety Study 1 2 Doses GlaxoSmithKline ( GSK ) Biologicals ' Meningococcal Vaccine MenACWY-TT ( GSK134612 ) Toddlers , Persistence 5 Years After Vaccination Co-administration With Pfizer 's Prevenar 13™Vaccine</brief_title>
	<detailed_description>The Medicines Control Council ( MCC ) authority request subject screen HIV test prior study enrolment South Africa ensure HIV negative participant enrol . As , HIV rapid test add Visit 1 subject South Africa . Subjects previously screen HIV positive exclude .</detailed_description>
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Subjects ' parent ( ) /Legally Acceptable Representative ( ) [ LAR ( ) ] , opinion investigator , comply requirement protocol . A male female , include , 12 14 month age time first vaccination . Written inform consent obtain parent ( ) /LAR ( ) subject . Healthy subject establish medical history clinical examination enter study . Vaccination record show completion full primary vaccination schedule Prevenar 13 Diphtheria , Tetanus Pertussis ( DTP ) contain vaccine accord local recommendation least 5 month study entry . Child care . Use investigational nonregistered product ( drug vaccine ) study vaccine within 30 day precede first dose study vaccine plan use study period . Chronic administration ( defined 14 day total ) immunosuppressant immunemodifying drug within six month prior first vaccine dose . For corticosteroid , mean prednisone 0.5 mg/kg/day , equivalent . Inhaled topical steroid allow . Planned administration/administration vaccine foreseen study protocol within period start 30 day end 30 day dose vaccine , exception license inactivated influenza vaccine . Measles , Mumps Rubella ( MMR ) vaccine Measles Mumps Rubella Varicella ( MMRV ) vaccine coadministered MenACWYTT and/or Prevenar 13 . A DTPa contain vaccine administer last blood sampling ( Visit 2 4 depend group ) . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational vaccine/product ( pharmaceutical product device ) . Previous vaccination Neisseria meningitidis . Previous booster vaccination Streptococcus pneumoniae . Previous booster vaccination Corynebacterium diphtheriae , Clostridium tetani Bordetella pertussis . History meningococcal disease . Any confirm suspected immunosuppressive immunodeficient condition ( congenital secondary ) , include human immunodeficiency virus ( HIV ) infection , base medical history physical examination ( laboratory testing require ) * Note : With exception HIV rapid test do subject South Africa . Family history congenital hereditary immunodeficiency . History reaction hypersensitivity , include diphtheria toxoid , likely exacerbated component vaccine . Major congenital defect serious chronic illness . History neurological disorder seizure , include GuillainBarré syndrome ( GBS ) . History simple , single febrile seizure permit . Acute disease and/or fever time enrollment . Administration immunoglobulins and/or blood product within 3 month precede first dose study vaccine plan administration study period .</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>14 Months</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Co-administration</keyword>
	<keyword>Safety</keyword>
	<keyword>Persistence</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Prevenar 13</keyword>
	<keyword>Meningococcal vaccine</keyword>
	<keyword>Toddlers</keyword>
	<keyword>5 year</keyword>
</DOC>